Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144163 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
A Phase 3 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 8
- Study locations
NCT07144163 is a Phase 3 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 150 participants, above the 84-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (79% higher). The trial reports 8 study locations across 7 states.
The verdict
NCT07144163, a Phase 3 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atumelnant
Study Locations (8)
Queensland
- Crinetics Study Site - Herston
- Crinetics Study Site - Woolloongabba
Michigan
- Crinetics Study Site - Ann Arbor
Buenos Aires F.D.
- Crinetics Study Site - Buenos Aires
South Australia
- Crinetics Study Site - Adelaide
Victoria
- Crinetics Study Site - Parkville
Western Australia
- Crinetics Study Site - Nedlands
São Paulo
- Crinetics Study Site - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144163
The ClinicalTrials.gov registry entry for NCT07144163 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (79% higher). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07144163 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Queensland, Michigan, Buenos Aires F.D..
Frequently Asked Questions
What is clinical trial NCT07144163 about?
NCT07144163 is a clinical study titled "A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia". The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
What is the current status of trial NCT07144163?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-12-11. Estimated completion is 2027-05.
What conditions does trial NCT07144163 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT07144163?
The interventions under investigation include: Placebo (DRUG), Atumelnant (DRUG).
Who is sponsoring clinical trial NCT07144163?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144163 being conducted?
This trial has 8 study locations across Michigan, Buenos Aires F.D., Queensland, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
-
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
ACTIVE NOT RECRUITING · Phase 3
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Congenital Adrenal Hyperplasia
All registered trials for this condition
Classic Congenital Adrenal Hyperplasia
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.